Similar studies for GEO DataSets (Select 4145) - GEO DataSets

Links from GEO DataSets

Items: 20

Select item 41451.

Subcutaneous Interferon-beta-1b treatment in relapsing-remitting multiple sclerosis (U133 A): peripheral mononuclear blood cells

Temporal analysis of PBMCs collected from 25 German relapsing-remitting multiple sclerosis patients treated with recombinant interferon-beta-1b (rIFN-β-1b, 250 µg every other day) for 2 years. Results provide insight into molecular mechanisms of IFN-b action.

Organism:: Homo sapiens

Type:: Expression profiling by array, count, 2 gender, 5 time sets

Platform:: GPL96
Series:: GSE24427
125 Samples

Download data: CEL

DataSet

Accession:: GDS4145

ID:: 4145

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Select item 2000334642.

Expression data of multiple sclerosis patients receiving subcutaneous Interferon-beta-1a therapy [U133 Plus 2.0]

(Submitter supplied) The purpose of this study was to characterize the transcriptional effects induced by subcutaneous IFN-beta-1a treatment (Rebif, 22 µg or 44 µg three times a week) in patients with relapsing-remitting form of multiple sclerosis (MS). By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells from 12 MS patients within the first two years of IFN-beta administration.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL14837
60 Samples

Download data: CEL

Series

Accession:: GSE33464

ID:: 200033464

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000244273.

Expression data of multiple sclerosis patients receiving subcutaneous Interferon-beta-1b therapy [U133 A and B]

(Submitter supplied) The purpose of this study was to characterize the transcriptional effects induced by subcutaneous IFN-beta-1b treatment (Betaferon, 250 µg every other day) in patients with relapsing-remitting form of multiple sclerosis (MS). By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells from 25 MS patients within the first two years of IFN-beta administration.

Organism:: Homo sapiens

Type:: Expression profiling by array

Datasets:: GDS4145 GDS4146
Platforms:: GPL96 GPL97
250 Samples

Download data: CEL

Series

Accession:: GSE24427

ID:: 200024427

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000192854.

Expression data of multiple sclerosis patients receiving intramuscular Interferon-beta-1a therapy [U133 A and B]

(Submitter supplied) The purpose of this study was to characterize the transcriptional effects induced by intramuscular IFN-beta-1a treatment (Avonex, 30 µg once weekly) in patients with relapsing-remitting form of multiple sclerosis (MS). By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells from 24 MS patients within the first four weeks of IFN-beta administration. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platforms:: GPL9741 GPL9742
144 Samples

Download data: CEL

Series

Accession:: GSE19285

ID:: 200019285

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 41465.

Subcutaneous Interferon-beta-1b treatment in relapsing-remitting multiple sclerosis (U133 B): peripheral mononuclear blood cells

Organism:: Homo sapiens

Type:: Expression profiling by array, count, 2 gender, 5 time sets

Platform:: GPL97
Series:: GSE24427
125 Samples

Download data: CEL

DataSet

Accession:: GDS4146

ID:: 4146

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Select item 2000055746.

Gene expression in PBMC from Multiple Sclerosis patients undergoing interferon beta therapy.

(Submitter supplied) We studied the gene expression patterns in PBMC from relapsing remitting MS patients undergoing weekly IFN-ß-1a therapy. On the basis of two fold changes in expression levels and statistical analyses we selected a diagnostic set of 137 genes that were differentially expressed between pretreatment and IFN-ß-1a-treated MS patients. Some these 137 genes may provide the basis for lack of IFN-ß-1a response. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS2419
Platform:: GPL4191
36 Samples

Download data

Series

Accession:: GSE5574

ID:: 200005574

Select item 24197.

Multiple sclerosis response to interferon beta-1a therapy: peripheral blood mononuclear cells

Analysis of peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis (MS) patients 1 day before, 1 day after, and up to 12 months after the initiation of interferon beta-1a (IFN-beta-1a) therapy. Results identify biomarkers for beta-IFN responsiveness.

Organism:: Homo sapiens

Type:: Expression profiling by array, count, 2 agent, 2 disease state, 6 individual, 4 time sets

Platform:: GPL4191
Series:: GSE5574
36 Samples

Download data

DataSet

Accession:: GDS2419

ID:: 2419

Select item 2000462938.

Expression data of multiple sclerosis patients receiving Interferon-beta therapy

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: synthetic construct; Homo sapiens

Type:: Expression profiling by array; Non-coding RNA profiling by array; Expression profiling by RT-PCR

4 related Platforms
78 Samples

Download data: CEL

Series

Accession:: GSE46293

ID:: 200046293

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000462929.

Expression data of multiple sclerosis patients receiving Interferon-beta therapy [TaqMan(r) Array Human MicroRNA B Cards v2.0]

(Submitter supplied) The purpose of this study was to investigate the expression dynamics of mRNAs and microRNAs in response to subcutaneous IFN-beta-1b treatment (Betaferon, 250 µg every other day) in patients with clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS) or relapsing-remitting type of the disease (RRMS). By using TaqMan Array MicroRNA Cards, we obtained microRNA expression profiles of peripheral blood mononuclear cells from 6 patients within the first month of IFN-beta treatment.

Organism:: Homo sapiens

Type:: Expression profiling by RT-PCR

Platform:: GPL13329
24 Samples

Download data: XLS

Series

Accession:: GSE46292

ID:: 200046292

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20004628310.

Expression data of multiple sclerosis patients receiving Interferon-beta therapy [TaqMan(r) Array Human MicroRNA A Cards v2.0]

Organism:: Homo sapiens

Type:: Expression profiling by RT-PCR

Platform:: GPL13328
24 Samples

Download data: XLS

Series

Accession:: GSE46283

ID:: 200046283

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20004628211.

Expression data of multiple sclerosis patients receiving Interferon-beta therapy [miRNA-2_0]

(Submitter supplied) The purpose of this study was to investigate the expression dynamics of mRNAs and microRNAs in response to subcutaneous IFN-beta-1b treatment (Betaferon, 250 µg every other day) in patients with clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS) or relapsing-remitting type of the disease (RRMS). By using Affymetrix microarrays, we obtained microRNA expression profiles of peripheral blood mononuclear cells from 3 patients within the first month of IFN-beta treatment.

Organism:: Homo sapiens; synthetic construct

Type:: Non-coding RNA profiling by array

Platform:: GPL14613
6 Samples

Download data: CEL

Series

Accession:: GSE46282

ID:: 200046282

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20004628012.

Expression data of multiple sclerosis patients receiving Interferon-beta therapy [HG-U133_Plus_2]

(Submitter supplied) The purpose of this study was to investigate the expression dynamics of mRNAs and microRNAs in response to subcutaneous IFN-beta-1b treatment (Betaferon, 250 µg every other day) in patients with clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS) or relapsing-remitting type of the disease (RRMS). By using Affymetrix microarrays, we obtained gene expression profiles of peripheral blood mononuclear cells from 6 patients within the first month of IFN-beta treatment.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL15445
24 Samples

Download data: CEL

Series

Accession:: GSE46280

ID:: 200046280

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20001065513.

Pharmacogenomics of IFNb therapy

(Submitter supplied) This experiment set is used for the manuscript entitled: Pharmacogenomics of Interferon-b therapy in multiple sclerosis: Baseline IFN signature determines pharmacological differences between patients. In this study we generated and analyzed pre- and post- IFNb treatment gene expression patterns of RRMS patients with the aim of identifying pre-existing and/or drug-induced signatures that will allow us to make predictions on the expected pharmacological effects of IFNb treatment. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6534
32 Samples

Download data

Series

Accession:: GSE10655

ID:: 200010655

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20003775014.

Gene expression data: Plasmacytoid dendritic cells (pDCs) of healthy donors and MS patientes before and after IFN beta treatment

(Submitter supplied) Multiple Sclerosis (MS) is an immune-mediated chronic inflammatory disease affecting the central nervous system. The cause of MS is not known and the mechanism of IFN-beta, a disease-modifying treatment (DMT) approved for MS, is not well-understood. Oligonucleotide microarrays were used to study gene expression in plasmacytoid denditic cells (pDCs) which are antigen-presenting cells implicated in MS pathogenesis. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
26 Samples

Download data: CEL

Series

Accession:: GSE37750

ID:: 200037750

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20005824015.

Gene expression profiling of the response to interferon beta in EBV-transformed and primary B cells of patients with multiple sclerosis

(Submitter supplied) To identify gene expression changes and pathways induced by interferon-β (IFN-β) in B cells, we studied the in vitro response of EBV-transformed B cells (lymphoblast cell lines-LCLs). LCLs were derived from an MS patient repository. Whole genome expression analysis identified 115 genes that were more than two-fold differentially up-regulated following IFN-β exposure, with over 50 novel IFN-β response genes. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL10558
32 Samples

Download data: TXT

Series

Accession:: GSE58240

ID:: 200058240

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20013806416.

Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection

(Submitter supplied) Background: In multiple sclerosis (MS), immune up-regulation is coupled to subnormal immune response to interferon-β (IFN-β) and low serum IFN-β levels. The relationship between the defect in IFN signalling and acute and long-term effects of IFN-β on gene expression in MS is inadequately understood. Methods: We profiled IFN-β-induced transcriptome shifts, using high-resolution microarrays on 227 mononuclear cell samples from IFN-β-treated MS Complete Responders (CR) stable for five years, and stable and active Partial Responders (PR), stable and active untreated MS, and healthy controls. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL17586
227 Samples

Download data: CEL

Series

Accession:: GSE138064

ID:: 200138064

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20000567817.

Profiling of interferon beta immediate transcriptional effects in humans

(Submitter supplied) In this study we used high frequency sampling and DNA microarrays to analyze the longitudinal transcriptional profile of blood cells taken from two individuals only hours after interferon beta administration and up to a week later as compared to samples taken from healthy controls taken at coordinated time points. Keywords: Time series

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL4228
130 Samples

Download data

Series

Accession:: GSE5678

ID:: 200005678

Select item 20012080818.

Genome-wide collaboration of canonical and non-canonical STAT1 complexes with NF-κB to control signal integration between Interferons and TLR4 in vascular and immune cells

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Mus musculus

Type:: Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing

Platform:: GPL17021
111 Samples

Download data: TDF

Series

Accession:: GSE120808

ID:: 200120808

PubMed Full text in PMC Similar studies

Select item 20012080719.

Genome-wide collaboration of canonical and non-canonical STAT1 complexes with NF-κB to control signal integration between Interferons and TLR4 in vascular and immune cells [RNA-seq]

(Submitter supplied) Atherosclerosis is a disease of large and medium-sized muscular arteries and is characterized by vascular inflammation and lipid-laden plaque formation within the intima of the vessel wall. Atherosclerosis is initiated by recruitment of blood leukocytes to the injured vascular endothelium and leads to altered contractility of Vascular Smooth Muscle Cells (VSMCs), acute and chronic luminal obstruction, abnormalities of blood flow and diminished oxygen supply to target organs. more...